Phase I/II clinical trial of encapsulated, cytochrome P450 expressing cells as local activators of cyclophosphamide to treat spontaneous canine tumours.

Based upon promising preclinical studies, a clinical trial was performed in which encapsulated cells overexpressing cytochrome P450 enzyme isoform 2B1 were implanted around malignant mammary tumours arising spontaneously in dogs. The dogs were then given cyclophosphamide, one of the standard chemoth...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Monika Michałowska, Stanislaw Winiarczyk, Łukasz Adaszek, Wojciech Łopuszyński, Zbigniew Grądzki, Brian Salmons, Walter H Günzburg
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4b821ea2311f40ed8bb05cb522000c32
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4b821ea2311f40ed8bb05cb522000c32
record_format	dspace
spelling	oai:doaj.org-article:4b821ea2311f40ed8bb05cb522000c322021-11-25T06:08:21ZPhase I/II clinical trial of encapsulated, cytochrome P450 expressing cells as local activators of cyclophosphamide to treat spontaneous canine tumours.1932-620310.1371/journal.pone.0102061https://doaj.org/article/4b821ea2311f40ed8bb05cb522000c322014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25028963/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Based upon promising preclinical studies, a clinical trial was performed in which encapsulated cells overexpressing cytochrome P450 enzyme isoform 2B1 were implanted around malignant mammary tumours arising spontaneously in dogs. The dogs were then given cyclophosphamide, one of the standard chemotherapeutic agents used for the treatment of mammary tumours. The dogs were assessed for a number of clinical parameters as well as for reduction in tumour size. The treatment was well tolerated with no evidence of adverse reactions or side effects being associated with the administration of the encapsulated cells. Reductions in tumour size of more than 50% were observed for 6 out of the 11 tumours analysed while 5 tumours showing minor responses, i.e. stable disease. In contrast, the tumours that received cyclophosphamide alone showed only stable disease. Taken together, this data suggests that encapsulated cytochrome P450 expressing cells combined with chemotherapy may be useful in the local treatment of a number of dog mammary tumours and support the performance of further clinical studies to evaluate this new treatment.Monika MichałowskaStanislaw WiniarczykŁukasz AdaszekWojciech ŁopuszyńskiZbigniew GrądzkiBrian SalmonsWalter H GünzburgPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 7, p e102061 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Monika Michałowska Stanislaw Winiarczyk Łukasz Adaszek Wojciech Łopuszyński Zbigniew Grądzki Brian Salmons Walter H Günzburg Phase I/II clinical trial of encapsulated, cytochrome P450 expressing cells as local activators of cyclophosphamide to treat spontaneous canine tumours.
description	Based upon promising preclinical studies, a clinical trial was performed in which encapsulated cells overexpressing cytochrome P450 enzyme isoform 2B1 were implanted around malignant mammary tumours arising spontaneously in dogs. The dogs were then given cyclophosphamide, one of the standard chemotherapeutic agents used for the treatment of mammary tumours. The dogs were assessed for a number of clinical parameters as well as for reduction in tumour size. The treatment was well tolerated with no evidence of adverse reactions or side effects being associated with the administration of the encapsulated cells. Reductions in tumour size of more than 50% were observed for 6 out of the 11 tumours analysed while 5 tumours showing minor responses, i.e. stable disease. In contrast, the tumours that received cyclophosphamide alone showed only stable disease. Taken together, this data suggests that encapsulated cytochrome P450 expressing cells combined with chemotherapy may be useful in the local treatment of a number of dog mammary tumours and support the performance of further clinical studies to evaluate this new treatment.
format	article
author	Monika Michałowska Stanislaw Winiarczyk Łukasz Adaszek Wojciech Łopuszyński Zbigniew Grądzki Brian Salmons Walter H Günzburg
author_facet	Monika Michałowska Stanislaw Winiarczyk Łukasz Adaszek Wojciech Łopuszyński Zbigniew Grądzki Brian Salmons Walter H Günzburg
author_sort	Monika Michałowska
title	Phase I/II clinical trial of encapsulated, cytochrome P450 expressing cells as local activators of cyclophosphamide to treat spontaneous canine tumours.
title_short	Phase I/II clinical trial of encapsulated, cytochrome P450 expressing cells as local activators of cyclophosphamide to treat spontaneous canine tumours.
title_full	Phase I/II clinical trial of encapsulated, cytochrome P450 expressing cells as local activators of cyclophosphamide to treat spontaneous canine tumours.
title_fullStr	Phase I/II clinical trial of encapsulated, cytochrome P450 expressing cells as local activators of cyclophosphamide to treat spontaneous canine tumours.
title_full_unstemmed	Phase I/II clinical trial of encapsulated, cytochrome P450 expressing cells as local activators of cyclophosphamide to treat spontaneous canine tumours.
title_sort	phase i/ii clinical trial of encapsulated, cytochrome p450 expressing cells as local activators of cyclophosphamide to treat spontaneous canine tumours.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/4b821ea2311f40ed8bb05cb522000c32
work_keys_str_mv	AT monikamichałowska phaseiiiclinicaltrialofencapsulatedcytochromep450expressingcellsaslocalactivatorsofcyclophosphamidetotreatspontaneouscaninetumours AT stanislawwiniarczyk phaseiiiclinicaltrialofencapsulatedcytochromep450expressingcellsaslocalactivatorsofcyclophosphamidetotreatspontaneouscaninetumours AT łukaszadaszek phaseiiiclinicaltrialofencapsulatedcytochromep450expressingcellsaslocalactivatorsofcyclophosphamidetotreatspontaneouscaninetumours AT wojciechłopuszynski phaseiiiclinicaltrialofencapsulatedcytochromep450expressingcellsaslocalactivatorsofcyclophosphamidetotreatspontaneouscaninetumours AT zbigniewgradzki phaseiiiclinicaltrialofencapsulatedcytochromep450expressingcellsaslocalactivatorsofcyclophosphamidetotreatspontaneouscaninetumours AT briansalmons phaseiiiclinicaltrialofencapsulatedcytochromep450expressingcellsaslocalactivatorsofcyclophosphamidetotreatspontaneouscaninetumours AT walterhgunzburg phaseiiiclinicaltrialofencapsulatedcytochromep450expressingcellsaslocalactivatorsofcyclophosphamidetotreatspontaneouscaninetumours
_version_	1718414098989842432

Phase I/II clinical trial of encapsulated, cytochrome P450 expressing cells as local activators of cyclophosphamide to treat spontaneous canine tumours.

Ejemplares similares